Baker Bros. Advisors’s Marker Therapeutics MRKR Stock Holding History

Baker Bros. Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-24,051	Closed	-$498K	–	122
2020 Q2	$498K	Sell	24,051 -122,969	-84%	-$2.69M	﹤0.01%	110
2020 Q1	$2.79M	Sell	147,020 -2,980	-2%	-$75.9K	0.02%	82
2019 Q4	$4.32M	Hold	150,000	–	–	0.02%	76
2019 Q3	$7.67M	Hold	150,000	–	–	0.05%	54
2019 Q2	$11.9M	Hold	150,000	–	–	0.08%	48
2019 Q1	$9.9M	Hold	150,000	–	–	0.06%	47
2018 Q4	$8.32M	Buy	+150,000	New	+$10.9M	0.07%	49

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Baker Bros. Advisors's MRKR Position: Q3 2020 in Review

Baker Bros. Advisors sold out of Marker Therapeutics (MRKR) in Q3 2020, closing a stake of 24,051 shares — an estimated $498K sold.

Baker Bros. Advisors first reported a position in MRKR in Q4 2018 and held it in 7 quarters. The position peaked at $11.9M in Q2 2019. 58 funds tracked by Wall St. Rank hold MRKR as of Q3 2020.

Baker Bros. Advisors reported no remaining Marker Therapeutics position as of Q3 2020 after selling out during the quarter.
Baker Bros. Advisors sold 24,051 Marker Therapeutics shares in Q3 2020, an estimated $498K.
Baker Bros. Advisors first reported a position in Marker Therapeutics in Q4 2018 and held it in 7 quarters.
Baker Bros. Advisors's Marker Therapeutics position peaked at $11.9M in Q2 2019.
58 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2020.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.